Novartis AG 2006 AR2
The report highlights Novartis' record financial and operational performance in 2006, with Group net sales increasing by 15% to USD 37.0 billion. The company expanded its strategic growth platforms through the acquisition of Chiron Corporation, establishing the new Vaccines and Diagnostics Division. In corporate citizenship, Novartis expanded its access-to-medicine programs, reaching 33.6 million patients with contributions valued at USD 755 million, including delivering 62 million treatment courses of the antimalarial Coartem. Additionally, the company made progress on its environmental goals, reducing halogenated VOC emissions and decreasing landfilled hazardous waste.
Company: Novartis AG
Sector: Manufacturing
Country: Switzerland
Year: 2006
Type: AR2
Pages: 236
Novartis AG
The report highlights Novartis' record financial and operational performance in 2006, with Group net sales increasing by 15% to USD 37.0 billion. The company expanded its strategic growth platforms through the acquisition of Chiron Corporation, establishing the new Vaccines and Diagnostics Division. In corporate citizenship, Novartis expanded its access-to-medicine programs, reaching 33.6 million patients with contributions valued at USD 755 million, including delivering 62 million treatment courses of the antimalarial Coartem. Additionally, the company made progress on its environmental goals, reducing halogenated VOC emissions and decreasing landfilled hazardous waste.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2006
Reporting Period
Jan 1, 2006 - Dec 31, 2006
Fiscal Year
2006
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Total Waste
Employees